Used in the pharmaceutical industry as a key intermediate in the synthesis of potent PARP (Poly ADP-ribose polymerase) inhibitors. These inhibitors are investigated for their anti-cancer properties, particularly in targeting tumors with deficiencies in DNA repair pathways, such as BRCA-mutated breast and ovarian cancers. The compound’s chiral structure enables selective interaction with biological targets, enhancing therapeutic efficacy and reducing off-target effects. It plays a critical role in optimizing the pharmacokinetic and binding properties of final drug candidates in oncology research.